NCT02713256View on ClinicalTrials.gov

A Study to Evaluate the Safety and Effect of CFZ533 on Patients With Graves' Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

April 19, 2016

Primary Completion Date

April 24, 2017

Study Completion Date

April 24, 2017

Conditions
Graves' Disease
Interventions
DRUG

CFZ533

CFZ533 intravenously over approximately one hour

Trial Locations (3)

55131

Novartis Investigative Site, Mainz

55905

Novartis Investigative Site, Rochester

96814

Novartis Investigative Site, Honolulu

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY